Paperpal Prime Logo

Expert Opinion on Emerging Drugs : Impact Factor & More

eISSN: 1744-7623pISSN: 1472-8214

Aims and Scope of Expert Opinion on Emerging Drugs

Expert Opinion on Emerging Drugs is a quarterly peer-reviewed medical journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas. Each review includes an "expert opinion" section, in which authors are asked to provide their personal view on the current status and future direction of the research discussed. It was established as Emerging Drugs in 1996, changing to its current name in 2001. It is published by Informa. According to the Journal Citation Reports, the journal has a 2014 impact factor of 3.058. Less

Key Metrics

CiteScore
5.6
Eigenfactor
0.001 - 0.005
H-Index
52
Impact Factor
< 5
SJR
Q1Pharmacology
SNIP
0.8
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Expert Opinion on Emerging Drugs

Expert Opinion on Emerging Drugs Journal Specifications

Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Quarterly
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year2001
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Expert Opinion on Emerging Drugs ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Expert Opinion on Emerging Drugs

PROTAC degraders for lymphoid malignancies - current status and future directions.
  • 23 Oct 2026
  • Expert opinion on emerging drugs
Emerging drugs for the treatment of gastrointestinal stromal tumors: a spotlight on bezuclastinib and the evolving treatment landscape
  • 15 Oct 2026
  • Expert Opinion on Emerging Drugs
Emerging therapies for pericarditis: from anti-IL-1 agents to novel therapeutic options
  • 5 Oct 2026
  • Expert Opinion on Emerging Drugs
Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra
  • 30 Sep 2026
  • Expert Opinion on Emerging Drugs
Emerging drugs for diabetic macular edema: an update
  • 25 Sep 2026
  • Expert Opinion on Emerging Drugs
Recent advances in hidradenitis suppurativa therapeutics: a focus on existing and future medical therapeutics
  • 11 Sep 2026
  • Expert Opinion on Emerging Drugs
PROTAC degraders for lymphoid malignancies - current status and future directions.
  • 23 Oct 2026
  • Expert opinion on emerging drugs
Emerging drugs for the treatment of gastrointestinal stromal tumors: a spotlight on bezuclastinib and the evolving treatment landscape
  • 15 Oct 2026
  • Expert Opinion on Emerging Drugs
Emerging therapies for pericarditis: from anti-IL-1 agents to novel therapeutic options
  • 5 Oct 2026
  • Expert Opinion on Emerging Drugs
Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra
  • 30 Sep 2026
  • Expert Opinion on Emerging Drugs
Emerging drugs for diabetic macular edema: an update
  • 25 Sep 2026
  • Expert Opinion on Emerging Drugs
Recent advances in hidradenitis suppurativa therapeutics: a focus on existing and future medical therapeutics
  • 11 Sep 2026
  • Expert Opinion on Emerging Drugs

FAQs on Expert Opinion on Emerging Drugs